The company also added two new directors to its board, keeping the "we're changing for the better!" headlines coming during an absence of news from Icahn. (One of the new directors is Robert Bertolini, former CFO and newly minted gazillionaire from Schering-Plough; the other is Ralph V. Whitworth, who represents Relational Investors.
During boardroom battles, every fault and foible of management may be seized upon by insurgent investors as they demand the votes of shareholders at upcoming annual meetings. Thus, Icahn may want to remind stockholders as they decide whether to vote for his directors' slate that Termeer's salary went from $1.6 million to to $1.7 million last year, despite a series of screwups at its Allston, Mass., facility, that cut drug production there and allowed rival companies to gain a foothold in what was once Genzyme's monopoly on drugs for certain rare genetic disorders.
Termeer's total compensation declined 25 percent from the year before as he gave up nearly $2 million in various cash benefits in his "Non-Equity Incentive Plan Compensation." However, that giveback was tempered by about $4 million in stock and $4 million in options, slightly less but comparable to the value he received the year before. That's crucial because the value of Genzyme's stock will likely remain depressed until its production problems are sorted out. Here's a chart that shows the decline of Genzyme stock last year:
Termeer's "other compensation" also rose to $124,000 from $116,000. Most of that was spent on a driver who ferries him from his lovely house in Marblehead Harbor, Mass., (pictured) to work. Here are Termeer's recent chauffeur, gas and lease expenses:
- $81,386 for 2009
- $73,599 for 2008
- $66,420 for 2007
- Genzyme's Dilemma: Its Cheap Cancer Drug Wants to Cannibalize a Potential MS Blockbuster
- Stop the Presses: Hapless Biotech Genzyme May Actually Be Doing Something Right
- Dead Man Walking? Genzyme CEO Still Breathing But Wall Street Sees a Corpse
- Genzyme CEO With "Zero Tolerance for Screwups" Has a 14-Year History of Them
- The Incompetent Monopolist: Genzyme's Drug Screwups Invite Attacks by Shire, Pfizer
- Look Behind Icahn's Battle for Control of Genzyme -- It's the ImClone War, Part Deux